Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
about
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective StudyActivation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.Astragalus polysaccharides increase the sensitivity of SKOV3 cells to cisplatin.Identification of candidate genes associated with tubal origin of high-grade serous ovarian cancer.
P2860
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
@ast
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
@en
type
label
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
@ast
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
@en
prefLabel
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
@ast
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
@en
P2093
P2860
P1433
P1476
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
@en
P2093
Bret M Hanlon
J Brian Szender
William H Bradley
P2860
P304
P356
10.1016/J.YGYNO.2015.09.011
P407
P50
P577
2015-09-14T00:00:00Z